Hyzaar is a fixed-dose combination pill that contains the active ingredients losartan and hydrochlorothiazide. Losartan belongs to the class of angiotensin II receptor blockers (ARBs), while hydrochlorothiazide is a thiazide-type diuretic. Each Hyzaar tablet delivers a standard amount of hydrochlorothiazide 12.5 mg together with a proprietary amount of losartan, formulated to help lower blood pressure in adults. In Hong Kong, Hyzaar is a prescription-only medication regulated by the Department of Health under the Pharmacy and Poisons Ordinance.
Losartan component - Blocks the angiotensin II type 1 (AT₁) receptors on blood vessels and the adrenal gland. By preventing angiotensin II from binding, losartan reduces vasoconstriction and the release of aldosterone, leading to relaxed arterial walls and lower blood pressure.
Hydrochlorothiazide component - Inhibits sodium-chloride reabsorption in the distal convoluted tubule of the kidney. Increased excretion of sodium and water reduces circulating blood volume, which also contributes to a drop in arterial pressure.
Combined effect - The ARB action provides sustained vasodilation, while the diuretic effect promptly reduces fluid overload. Together, they produce a synergistic reduction in systolic and diastolic blood pressure, helping to achieve target levels more efficiently than either agent alone.
Onset and duration - Blood-pressure-lowering effects typically begin within a few hours after the first dose, with the full therapeutic effect reached after several days of consistent daily dosing. The antihypertensive effect persists for most of the 24-hour dosing interval.
Hyzaar is approved by the Hong Kong Department of Health for the treatment of primary hypertension (high blood pressure) in adult patients. It is indicated when a single-agent therapy does not achieve adequate blood-pressure control, or when a clinician wishes to combine an ARB with a thiazide diuretic for added efficacy. The medication is intended for patients with no contraindications to either component and is usually part of a broader cardiovascular-risk-reduction plan that includes lifestyle modification.
Current peer-reviewed literature reports occasional off-label investigation of losartan-based combinations for conditions such as diabetic nephropathy and certain forms of heart failure. These uses are not approved by Hong Kong regulatory authorities. Off-label use requires careful medical supervision, individualized risk assessment, and close monitoring of renal function and electrolytes.
Major interactions
Potassium-sparing agents (e.g., spironolactone, amiloride) - increase risk of hyperkalemia when combined with losartan.
Non-steroidal anti-inflammatory drugs (NSAIDs) - may blunt antihypertensive effect and impair renal function.
Moderate interactions
Other antihypertensives (e.g., ACE inhibitors, beta-blockers) - additive blood-pressure lowering; dose titration may be required.
Lithium - thiazide component can raise lithium levels, increasing toxicity risk.
CYP2C9 substrates (e.g., warfarin) - losartan is metabolized partly by CYP2C9; monitor INR closely if co-prescribed.
This article provides educational information about Hyzaar and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, Hyzaar may be combined with other antihypertensive agents, but clinicians usually adjust doses to avoid excessive blood-pressure lowering. Monitoring for additive effects such as dizziness or orthostatic hypotension is essential.
A cough is more commonly associated with ACE inhibitors than with ARBs. While losartan is less likely to cause cough, any new respiratory symptom should be evaluated by a healthcare professional to rule out unrelated causes.
Hydrochlorothiazide can increase serum uric acid, potentially aggravating gout. Patients with gout should discuss alternative antihypertensives or close monitoring of uric acid levels with their provider.
The thiazide component may lower potassium (hypokalemia), whereas losartan can modestly raise potassium. Regular testing is recommended, and potassium supplements may be considered if levels fall below the normal range.
Yes, Hyzaar is a prescription medication. Carry the original pharmacy label and a copy of the prescription, and declare the medication if required by the destination country's customs regulations.
Hyzaar is not a prohibited substance in standard drug-screening panels. However, athletes subject to anti-doping rules should verify that the medication is allowed under their sport’s specific regulations.
Hyzaar tablets are typically round, film-coated, and bear a distinct imprint that varies by manufacturer. In Hong Kong, they often display a color-coded logo indicating the fixed-dose combination.
No, Hyzaar tablets are stable at ordinary room temperature. They should be kept away from excessive heat and humidity but do not need refrigeration.
Generic formulations containing losartan and hydrochlorothiazide in the same fixed-dose ratio are available. Patients should consult their pharmacist for brand-specific information and cost considerations.
Blood pressure should be measured within the first week of therapy to assess response, then regularly (e.g., monthly) until stable control is achieved, after which routine check-ups every 3-6 months are typical.
